查看文章

Background

HER3, a member of the epidermal growth factor family, is aberrantly expressed in lung cancer. It is a promising target for treatment with many antibody-drug conjugates (ADCs) developed, including Patritumab deruxtecan. In our study we aim to evaluate the difference between HER3 high and low groups based on a comprehensive multiomics analyses.

Methods

We utilized The Cancer Genomic Atlas lung adenocarcinoma (LUAD) project data. Clinical, histopathological, genomic, and proteomic data for 599 LUAD patients was retrieved through the cBioPortal database. Patients with the highest and lowest 25% HER3 mRNA expression were grouped into the high-and low-HER3 groups, respectively. Differential gene expression analysis was conducted using the DESeq2 R package and enrichment analysis for upregulated genes was done using the gene ontology (GO) and KEGG pathways libraries …